Scheduled to open in 2021, the new center will study the therapeutic potential of MDMA, psilocybin, DMT, and mescaline.
Eleusis’s Phase I Alzheimer’s Trial Finds Favorable Safety & Tolerability of LSD in Older Volunteers
There were no abnormalities or deviations in safety or cognitive outcome measures compared to the baseline data.
Some changes occured to biomarkers for stress and inflammation. The subjective effects reveal more evidence of the entourage effect.
The study will examine the effects of microdosing LSD on the everyday lives of the participants.
Psychedelics disrupt the brain networks responsible for the feeling of selfhood.
Real-time gathering of physiological data and subjective effects give clues that may help define a microdose of psilocybin.
Usona Follows COMPASS in Receiving Breakthrough Therapy Designation for Psilocybin to Treat Depression
This means the FDA will work to expedite the development and review of psilocybin so it can get to patients with major depressive disorder as soon as possible.
A look into the less discussed therapeutic aspect of psychedelics: the anti-inflammatory effect.
As psychedelic research moves ahead, some have started to identify several topics of significant interest to women.
Usona Institute Beginning Phase 2 Clinical Trials Using Psilocybin to Treat Major Depressive Disorder
Enrollment of study volunteers is expected to start within the next two months.